LATEST HEALTH NEWS
Enzalutamide reduced metastasis or death risk by 71 percent in phase III trial of castration-resistant nonmetastatic prostate cancer with escalating PSA.
from Featured Health News from Medical News Today https://ift.tt/2tRVuIM
from Featured Health News from Medical News Today https://ift.tt/2tRVuIM
No comments
Thanks for comment via will connect you within 24 hours.